Inventor · disambiguated record
Likan Liang
Also filed as: LIANG LIKAN
30 granted patents·10 pending applications·330 citations·filing 1997–2021
97Inventor score
Files withSUPERNUS PHARMACEUTICALS INC24LIANG LIKAN7CONSTANTINIDES PANAYIOTIS P3ORASOMOL TECHNOLOGIES INC2SHIRE LAB INC2
Top patents by PatentIndex Score
40 records- 0197US8598191B2Controlled release compositions of gamma-hydroxybutyrateLIANG LIKAN·Filed 2012·Granted Dec 3, 2013·76 cites·15 claims
- 0297US8193211B2Controlled release compositions of gamma-hydroxybutyrateLIANG LIKAN·Filed 2005·Granted Jun 5, 2012·87 cites·30 claims
- 0392US8298580B2Sustained-release formulations of topiramateLIANG LIKAN·Filed 2010·Granted Oct 30, 2012·12 cites·31 claims
- 0492US6500453B2Polymerizable fatty acids, phospholipids and polymerized liposomes therefromORASOMOL TECHNOLOGIES INC·Filed 2001·Granted Dec 31, 2002·44 cites·11 claims
- 0590US8957206B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Feb 17, 2015·5 cites·28 claims
- 0689US8748472B2Stabilized formulations of CNS compoundsCHANG RONG-KUN·Filed 2011·Granted Jun 10, 2014·11 cites·44 claims
- 0785US8663683B2Sustained-release formulations of topiramateLIANG LIKAN·Filed 2012·Granted Mar 4, 2014·4 cites·24 claims
- 0884US11077114B2Stabilized formulations of CNS compoundsSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Aug 3, 2021·1 cites·28 claims
- 0982US9403783B2Methods for producing viloxazine salts and novel polymorphs thereofLIANG LIKAN·Filed 2011·Granted Aug 2, 2016·6 cites·7 claims
- 1078US7022337B2Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effectSHIRE LAB INC·Filed 2003·Granted Apr 4, 2006·17 cites·19 claims
- 1178US6511677B1Polymerizable fatty acids, phospholipids and polymerized liposomes therefromORASOMOL TECHNOLOGIES INC·Filed 2000·Granted Jan 28, 2003·10 cites·5 claims
- 1278US6187335B1Polymerizable fatty acids, phospholipids and polymerized liposomes therefromORASOMAL TECHNOLOGIES INC·Filed 1997·Granted Feb 13, 2001·46 cites·8 claims
- 1377US10149853B2Stabilized formulations of CNS compoundsSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Dec 11, 2018·2 cites·22 claims
- 1477US8298576B2Sustained-release formulations of topiramateLIANG LIKAN·Filed 2007·Granted Oct 30, 2012·1 cites·30 claims
- 1576US2022024885A1Methods for producing viloxazine salts and novel polymorphs thereofSUPERNUS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1675US8889191B2Sustained-release formulations of topiramateLIANG LIKAN·Filed 2010·Granted Nov 18, 2014·1 cites·24 claims
- 1774US11117862B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2020·Granted Sep 14, 2021·0 cites·8 claims
- 1873US10005743B2Methods for producing viloxazine salts and novel polymorphs thereofSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Jun 26, 2018·1 cites·12 claims
- 1972US2021322429A1Stabilized formulations of cns compoundsSUPERNUS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2069US10676432B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·0 cites·13 claims
- 2169US8992989B2Sustained-release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Mar 31, 2015·0 cites·20 claims
- 2268US8877248B1Sustained-release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Nov 4, 2014·0 cites·20 claims
- 2367US10314790B2Sustained-release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Jun 11, 2019·0 cites·25 claims
- 2465US10160733B2Methods for producing viloxazine salts and novel polymorphs thereofSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Dec 25, 2018·0 cites·6 claims
- 2565US10081595B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Sep 25, 2018·0 cites·20 claims
- 2665US9622983B2Sustained-release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Apr 18, 2017·0 cites·30 claims
- 2765US9549940B2Sustained-release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Jan 24, 2017·0 cites·20 claims
- 2865US9434703B2Viloxazine compositionsSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 6, 2016·0 cites·5 claims
- 2964US8535650B2Stabilized reverse micelle compositions and uses thereofCONSTANTINIDES PANAYIOTIS P·Filed 2002·Granted Sep 17, 2013·6 cites·18 claims
- 3063US9802893B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Oct 31, 2017·0 cites·18 claims
- 3163US2019300492A1Methods for producing viloxazine salts and novel polymorphs thereofSUPERNUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3261US9562011B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2015·Granted Feb 7, 2017·0 cites·17 claims
- 3361US9555004B2Sustained-release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2015·Granted Jan 31, 2017·0 cites·15 claims
- 3457US2005191343A1Micellar systems useful for delivery of lipophilic or hydrophobic compoundsSHIRE LAB INC·Filed 2004·Application pending·0 cites
- 3557US2008131501A1Enhanced immediate release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 3656US2014037745A1Controlled release compositions of gamma-hydroxybutyrateSUPERNUS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3754US2015024055A1Enhanced immediate release formulations of topiramateSUPERNUS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3846US2006104997A1Monoterpene compositions and uses thereofCONSTANTINIDES PANAYIOTIS P·Filed 2002·Application pending·0 cites
- 3946US2006078618A1Lipid particles and suspensions and uses thereofCONSTANTINIDES PANAYIOTIS P·Filed 2002·Application pending·0 cites
- 4044US2010209489A1Formulations of desvenlafaxineSUPERNUS PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Likan Liang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →